Filter Results:
(1,248)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- Web
Strategy for Health Care Delivery - Institute For Strategy And Competitiveness
Clinic) as part of their business model Senior executives from nonprofit organizations that deliver health care services Executives from health care insurance companies, government entities that pay for health care, or other payor organizations Leaders from View Details
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- Web
Value Measurement for Health Care - Institute For Strategy And Competitiveness
part of their business model Executives from health care insurance companies, government entities that pay for health care, or other payor organizations Leaders from pharmaceutical companies, medical device companies, or other health care... View Details
- September 1990 (Revised November 1991)
- Case
Merck & Co., Inc. (B)
In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major... View Details
Murphy, Kevin J. "Merck & Co., Inc. (B)." Harvard Business School Case 491-006, September 1990. (Revised November 1991.)
- 01 Jun 2023
- News
From Big Pharma to Startup
pharmaceutical giant one day—not creating a company from scratch. But Goble was determined to explore the wide variety of opportunities available to him in his time at HBS, so when he read about a nonprofit life sciences entrepreneurship... View Details
Keywords: April White
Stephen P. Bradley
Professor Bradley is the William Ziegler Professor of Business Administration Emeritus at the Harvard Business School. In addition to teaching Management and Strategy in the Owner President Management Program and leading an... View Details
- 01 Sep 2007
- News
Alfred D. Chandler Jr. Remembered
Matsushita. That volume was followed in 2005 by Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. “Such science-based industries have had as much impact on this... View Details
- 31 May 2023
- News
Alumni Achievement Awards 2023
A. Schwarzman (MBA 1972) Reshma Kewalramani MD, FASN (GMP 18, 2015) CEO and President, Vertex Pharmaceuticals Big move: “I was almost 12 when we flew from Bombay to the United States. My impressions of the West came from the movie Grease... View Details
- November 2016
- Case
Transformation at Eli Lilly & Co. (A)
By: William R. Kerr and Alexis Brownell
Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,... View Details
Keywords: Eli Lilly; Restructuring; R&D; Transformation; Organizational Change and Adaptation; Organizational Structure; Pharmaceutical Industry; Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (A)." Harvard Business School Case 817-070, November 2016.
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
- January 1998 (Revised February 2006)
- Background Note
Creating Competitive Advantage
By: Pankaj Ghemawat and Jan W. Rivkin
A firm such as Schering-Plough that earns superior, long-run financial returns within its industry is said to enjoy a competitive advantage over its rivals. This note examines the logic of how firms create competitive advantage. It emphasizes two themes: First, to... View Details
Keywords: Competitive Advantage; Competitive Strategy; Management; Business Strategy; Growth and Development Strategy; Innovation Strategy; Management Practices and Processes; Value Creation; Pharmaceutical Industry
Ghemawat, Pankaj, and Jan W. Rivkin. "Creating Competitive Advantage." Harvard Business School Background Note 798-062, January 1998. (Revised February 2006.)
- Web
Research - Health Care
UAE for fibroids or adenomyosis were captured from electronic health record timestamps and... May 2024 Article Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms By: Caroline Marra... View Details
- April 2011 (Revised April 2015)
- Case
Cipla 2011
By: Rohit Deshpande, Sandra J. Sucher and Laura Winig
Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details
Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry
Deshpande, Rohit, Sandra J. Sucher, and Laura Winig. "Cipla 2011." Harvard Business School Case 511-050, April 2011. (Revised April 2015.)
William E. Fruhan
Professor WILLIAM E. FRUHAN, JR. is George E. Bates Professor, Emeritus at the Harvard Business School. He received his BS degree from Yale University, and his MBA and DBA degrees from Harvard University. He has served as Senior Associate Dean and Director of... View Details
- 01 Oct 2021
- News
From Scholarship to Life-Saving Impact
ending up with huge medical bills we couldn’t pay.” Inspired by this personal experience, Rabah chose to build a career in health care. She studied biology as an undergraduate at Cornell, where she developed a strong interest in drug pricing and View Details
- Web
Request more information | HBS Courses | HBS Online
Aerospace/Defense Agriculture Auto Communications E-Commerce E-Education Energy Entertainment Financial Services Food/Beverage Health/Medical Hospitality Insurance Manufacturing Non-Profit Pharmaceuticals Professional Services Retail... View Details
- Web
Strategy Awards & Honors - Faculty & Research
her paper with Ian Cockburn, "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research" ( Strategic Management Journal , 1994). The award is for a paper published five or more years prior so that the paper's impact on... View Details
- 22 Nov 2004
- Research & Ideas
Side Effects: The Case of Propecia
You are the marketing director of Propecia, a new drug for hair restoration that's about to hit the market. But the drug can only be purchased via a physician's prescription. So do you advertise directly to balding men? Do you concentrate on targeting physicians? How... View Details